⚠️

Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.

COVID-19 Vaccine2023

COVID-19 Vaccine in 2023

54,720 adverse event reports (-75% vs 2022)

Share
54,720
Reports
2,087
Deaths
13,999
Hospitalizations
4,038
ER Visits
2,119
Disabilities

2023 Reporting Summary

In 2023, 54,720 adverse event reports were filed for COVID-19 Vaccine in VAERS. This represents 4.9% of all 1,121,388 reports for this vaccine.

Of these reports, 2,087 mentioned death, 13,999 involved hospitalization, 4,038 required ER visits, and 2,119 reported disability.

Compared to the average of 153,760 reports per year for this vaccine, 2023 was below average (-64%).

💡 What This Means

High report volume: 54,720 reports in a single year is significant. This typically reflects large-scale vaccination campaigns rather than increased risk per dose. Without knowing total doses administered in 2023, raw report counts cannot indicate safety rates.

Death reports require context: 2,087 death reports does not mean the vaccine caused 2,087 deaths. VAERS accepts all reports regardless of causation. Many recipients are elderly or have comorbidities, and background mortality rates must be considered.

All Years for COVID-19 Vaccine

YearReportsDeathsHosp.
20265002072
202510,6445401,211
202420,2468242,117
2023 ← current54,7202,08713,999
2022221,5808,13338,360
2021757,74712,95558,027
202010,88316155

Understanding Yearly Data

Spikes may reflect awareness: Years with unusual activity (e.g., pandemic) often see increased reporting.
Dose volume matters: More vaccinations given in a year naturally leads to more reports.
Reporting lag: Some events are reported months after they occur, so recent years may be incomplete.

Quick Facts

Reports:54,720
Deaths:2,087
Hospitalizations:13,999
% of Total:4.9%
Rank (by vol.):#3 of 7 years
Avg/year:153,760

Data Source

This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.